fluoxetine has been researched along with Seasonal Affective Disorder in 17 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Seasonal Affective Disorder: A syndrome characterized by depressions that recur annually at the same time each year, usually during the winter months. Other symptoms include anxiety, irritability, decreased energy, increased appetite (carbohydrate cravings), increased duration of sleep, and weight gain. SAD (seasonal affective disorder) can be treated by daily exposure to bright artificial lights (PHOTOTHERAPY), during the season of recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors investigated the efficacy and safety of fluoxetine in the treatment of winter seasonal affective disorder." | 9.08 | Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. ( Corral, MR; Gorman, CP; Joffe, RT; Lam, RW; Levitt, AJ; Michalon, M; Morehouse, RL; Steiner, M; Tam, W; Watson, GD, 1995) |
| " This study investigated whether fluoxetine has antidepressant effects comparable to bright light in the treatment of seasonal affective disorder (winter type)." | 9.08 | Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. ( Hawellek, B; Höflich, G; Kasper, S; Martinez, B; Möller, HJ; Nickelsen, T; Ruhrmann, S, 1998) |
| "The aim was to investigate the secretion profile of melatonin and seasonal affective disorder before and after treatment with fluoxetine." | 7.69 | Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. ( Allen, NH; Childs, PA; Martin, NJ; Plaskett, L; Rodin, I; Smythe, PJ; Thompson, C, 1995) |
| "Fluoxetine was associated with greater treatment-emergent adverse events (agitation, sleep disturbance, palpitations), but both treatments were generally well-tolerated with no differences in overall number of adverse effects." | 6.72 | The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. ( Enns, MW; Lam, RW; Levitan, RD; Levitt, AJ; Michalak, EE; Morehouse, R; Tam, EM, 2006) |
| "The authors investigated the efficacy and safety of fluoxetine in the treatment of winter seasonal affective disorder." | 5.08 | Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. ( Corral, MR; Gorman, CP; Joffe, RT; Lam, RW; Levitt, AJ; Michalon, M; Morehouse, RL; Steiner, M; Tam, W; Watson, GD, 1995) |
| " This study investigated whether fluoxetine has antidepressant effects comparable to bright light in the treatment of seasonal affective disorder (winter type)." | 5.08 | Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. ( Hawellek, B; Höflich, G; Kasper, S; Martinez, B; Möller, HJ; Nickelsen, T; Ruhrmann, S, 1998) |
| "The aim was to investigate the secretion profile of melatonin and seasonal affective disorder before and after treatment with fluoxetine." | 3.69 | Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. ( Allen, NH; Childs, PA; Martin, NJ; Plaskett, L; Rodin, I; Smythe, PJ; Thompson, C, 1995) |
| "Fluoxetine was associated with greater treatment-emergent adverse events (agitation, sleep disturbance, palpitations), but both treatments were generally well-tolerated with no differences in overall number of adverse effects." | 2.72 | The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. ( Enns, MW; Lam, RW; Levitan, RD; Levitt, AJ; Michalak, EE; Morehouse, R; Tam, EM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Mittal, M | 1 |
| Goel, RK | 1 |
| Bhargava, G | 1 |
| Mahajan, MP | 1 |
| Belge, JB | 1 |
| Sabbe, AC | 1 |
| Sabbe, BG | 1 |
| Nussbaumer-Streit, B | 1 |
| Thaler, K | 2 |
| Chapman, A | 2 |
| Probst, T | 1 |
| Winkler, D | 1 |
| Sönnichsen, A | 1 |
| Gaynes, BN | 2 |
| Gartlehner, G | 2 |
| Kawai, M | 1 |
| Goda, R | 1 |
| Otsuka, T | 1 |
| Iwamoto, A | 1 |
| Uotsu, N | 1 |
| Furuse, M | 1 |
| Yasuo, S | 1 |
| Delivuk, M | 1 |
| Kaminski, A | 1 |
| Swiecicki, Ł | 1 |
| Szafrański, T | 1 |
| Sakamoto, K | 1 |
| Murray, G | 3 |
| Michalak, EE | 5 |
| Levitt, AJ | 6 |
| Levitan, RD | 5 |
| Enns, MW | 5 |
| Morehouse, R | 5 |
| Lam, RW | 7 |
| Cox, BJ | 1 |
| Tam, EM | 3 |
| Cheung, A | 1 |
| Childs, PA | 1 |
| Rodin, I | 1 |
| Martin, NJ | 1 |
| Allen, NH | 1 |
| Plaskett, L | 1 |
| Smythe, PJ | 1 |
| Thompson, C | 1 |
| Gorman, CP | 1 |
| Michalon, M | 1 |
| Steiner, M | 1 |
| Corral, MR | 1 |
| Watson, GD | 1 |
| Morehouse, RL | 1 |
| Tam, W | 1 |
| Joffe, RT | 1 |
| Partonen, T | 1 |
| Lönnqvist, J | 1 |
| Ruhrmann, S | 1 |
| Kasper, S | 1 |
| Hawellek, B | 1 |
| Martinez, B | 1 |
| Höflich, G | 1 |
| Nickelsen, T | 1 |
| Möller, HJ | 1 |
| Lee, SK | 1 |
| Grewal, A | 1 |
| Yatham, LN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder[NCT00502320] | Phase 4 | 50 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinician-rated measure of mood; evaluates classical 21 Hamilton Depression items, and 8-item subscale measuring atypical depression symptoms which commonly occur during SAD episodes. Score ranges from 0-89, higher scores indicate higher levels of depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
| Placebo | 19.99 | 15.97 | 19.47 | 20.65 | 23.68 |
| Ramelteon | 22.68 | 16.16 | 14.81 | 11.69 | 9.15 |
Self-rated scale to measure severity of depressive symptoms. Score ranges from 25-100, higher scores reflect more depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
| Placebo | 58.63 | 56.40 | 58.59 | 58.62 | 61.65 |
| Ramelteon | 63.06 | 54.35 | 53.51 | 49.26 | 46.14 |
Self-rated scale to measure quality of sleep via questions regarding sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction. Score ranges from 0-21, higher scores represent more significant sleep disturbance. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
| Placebo | 11.45 | 8.67 | 8.62 | 9.88 | 9.61 |
| Ramelteon | 11.56 | 9.52 | 7.57 | 8.07 | 7.05 |
3 reviews available for fluoxetine and Seasonal Affective Disorder
| Article | Year |
|---|---|
Second-generation antidepressants for treatment of seasonal affective disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Bias; Citalopram; Duloxetine Hydrochloride; Female; | 2021 |
Second-generation antidepressants for seasonal affective disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Duloxetine Hydrochloride; Female; Fluox | 2011 |
[Seasonal affective disorder].
Topics: Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Humans; Male; Moclobemide | 2003 |
9 trials available for fluoxetine and Seasonal Affective Disorder
| Article | Year |
|---|---|
Therapeutic mechanism in seasonal affective disorder: do fluoxetine and light operate through advancing circadian phase?
Topics: Adolescent; Adult; Aged; Circadian Rhythm; Fluoxetine; Humans; Light; Middle Aged; Seasonal Affectiv | 2005 |
O sweet spot where art thou? Light treatment of Seasonal Affective Disorder and the circadian time of sleep.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Circadian Rhythm; Combined Modali | 2006 |
Personality and seasonal affective disorder: results from the CAN-SAD study.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Diagnosis, Differential; Femal | 2006 |
The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder.
Topics: Adult; Canada; Combined Modality Therapy; Diagnostic and Statistical Manual of Mental Disorders; Dou | 2006 |
Quality of life as an outcome indicator in patients with seasonal affective disorder: results from the Can-SAD study.
Topics: Adult; Canada; Double-Blind Method; Female; Fluoxetine; Humans; Male; Phototherapy; Prospective Stud | 2007 |
Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Humans; Male; | 1995 |
Moclobemide and fluoxetine in treatment of seasonal affective disorder.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzamides; Dose-Respo | 1996 |
Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder.
Topics: Adult; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Phototherapy; Seasonal Af | 1998 |
An open trial of light therapy for women with seasonal affective disorder and comorbid bulimia nervosa.
Topics: Adolescent; Adult; Bulimia; Comorbidity; Female; Fluoxetine; Fluvoxamine; Humans; Multi-Institutiona | 2001 |
5 other studies available for fluoxetine and Seasonal Affective Disorder
| Article | Year |
|---|---|
PASS-assisted exploration of antidepressant activity of 1,3,4-trisubstituted-beta-lactam derivatives.
Topics: Animals; Antidepressive Agents; Chemistry, Pharmaceutical; Computational Biology; Crystallography, X | 2008 |
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?
Topics: Fluoxetine; Humans; Phototherapy; Seasonal Affective Disorder | 2022 |
Antidepressant-like effect of bright light is potentiated by L-serine administration in a mouse model of seasonal affective disorder.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Disease Models, Animal; Fluoxetine; Light; | 2015 |
Side effects after phototherapy implementation in addition to fluoxetine or sertraline treatment: a report of two cases.
Topics: Adult; Drug Synergism; Female; Fluoxetine; Humans; Male; Middle Aged; Phototherapy; Seasonal Affecti | 2002 |
Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls.
Topics: Adult; Female; Fluoxetine; Humans; Hypothalamus; Male; Melatonin; Receptors, Adrenergic, beta-1; Sea | 1995 |